RETATRUTIDE (15mg)

Retatrutide is a first-in-class triple agonist of GLP-1, GIP, and glucagon receptors currently in Phase 3 clinical trials. By simultaneously engaging three complementary metabolic receptor pathways, it has produced the most significant body weight reductions observed in peer-reviewed pharmacological research. Phase 2 data reported average weight reductions of up to 24% of body weight.

Mechanism of Action

•        Activates GLP-1 receptors, studied for appetite reduction, delayed gastric emptying, and glucose-dependent insulin secretion.

•        Activates GIP receptors, investigated for insulin release enhancement and potential adipose tissue lipolysis.

•        Activates glucagon receptors, driving caloric expenditure and hepatic fatty acid oxidation in metabolic models.

•        Triple agonism produces synergistic metabolic effects not observed with dual or single receptor agonism alone.

•        Preclinical and clinical research suggests direct reduction in hepatic fat content, relevant to NAFLD/NASH biology.

Research Areas

•        Obesity and overweight pharmacology research with unmatched weight reduction observations to date.

•        Type 2 diabetes and comprehensive glycemic control studies.

•        Metabolic syndrome research addressing multiple cardiometabolic risk factors simultaneously.

•        NAFLD and NASH biology research.

•        Body recomposition studies examining fat loss alongside muscle mass preservation.

Presentation and Storage

Supplied as a lyophilized powder in a sealed vial containing 15mg of retatrutide. Reconstitute with bacteriostatic water for laboratory use. Store at -20C.